ArticleResearch square2026
Development of a noninvasive murine model of hyperthermic intraperitoneal chemotherapy (HIPEC) treatment for ovarian cancer.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Ovarian cancer (OC) is currently the leading cause of death from gynecological cancer, with 60% of cases ending in mortality. As an aggressive disease of the female reproductive system, OC in the advanced stage metastasizes to the peritoneum, and ascites is present in > 90% of patients with stage III-IV disease. This accumulation of fluid in the abdomen is associated with a 5% survival rate. Current therapeutic strategies exist for treating OC, yet tumors recur and become chemoresistance, indicating a critical need for improved therapeutics. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a successful treatment given to select patients with advanced disease. HIPEC involves pumping heated chemotherapy throughout the peritoneal cavity at time of debulking surgery. HIPEC has shown success in treating advanced OC by extending overall survival by nearly 12 months, yet the mechanisms of benefit remain unknown. A rapid noninvasive animal model is lacking for the study of HIPEC. This poses a significant barrier for improving HIPEC protocols for patient benefit. We have developed the first noninvasive animal model by using external abdominal heat with chemotherapy. Results reveal significant attenuation of tumor growth, delayed tumor-associated ascites development, and extended survival after treatment with hyperthermic chemotherapy compared to normothermic cisplatin treatment. This method is rapidly allowing for multiple mouse treatments per procedure. Our findings show hyperthermic chemotherapy delays ascites onset and extend survival. This non-invasive model allows for implementation of mechanistic studies to investigate HIPEC survival benefit. Elucidating these mechanisms is essential to enhance HIPEC benefit and identifying strategies to define less invasive therapeutic mechanisms for the treatment of ovarian cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.